Buntanetap
Alzheimer's Disease
Key Facts
About Annovis Bio
Annovis Bio is a Phase 3 neuroscience biotech developing buntanetap, an oral translational inhibitor designed to reduce multiple neurotoxic proteins (APP, tau, α-synuclein) to restore axonal transport and stop neuronal death. The company's strategy targets a common upstream mechanism in Alzheimer's and Parkinson's disease, differentiating it from monoclonal antibody competitors. With late-stage trials underway, Annovis aims to deliver a first-in-class, disease-modifying therapy for major neurodegenerative conditions with high unmet need.
View full company profileAbout Annovis Bio
Annovis Bio is a Phase 3 neuroscience biotech developing buntanetap, an oral translational inhibitor designed to reduce multiple neurotoxic proteins (APP, tau, α-synuclein) to restore axonal transport and stop neuronal death. The company's strategy targets a common upstream mechanism in Alzheimer's and Parkinson's disease, differentiating it from monoclonal antibody competitors. With late-stage trials underway, Annovis aims to deliver a first-in-class, disease-modifying therapy for major neurodegenerative conditions with high unmet need.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | Johnson and Johnson Innovative Medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| PMN310 | ProMIS Neurosciences | Phase 1b |